Etoposide addition and brentuximab vedotin consolidation in first-line treatment of CD30-positive peripheral T-cell lymphoma: can we improve BV-CHP?
Mené sur 48 patients atteints d'un lymphome périphérique à cellules T surexprimant CD30, cet essai multicentrique de phase II évalue l'efficacité, du point de vue du taux de réponse complète, et la toxicité d'une chimiothérapie de première ligne de type CHEP-BV (brentuximab védotin, cyclophosphamide, doxorubicine, étoposide et prednisone) suivie du brentuximab védotin en traitement de consolidation
Despite extensive efforts to improve the prognosis for people with peripheral T-cell lymphoma, patient outcomes are still disappointingly poor. 1 , 2 This lack of improvement is especially striking when compared with the significantly improved outcomes in patients with non-Hodgkin B-cell lymphoma, who have benefited from therapeutic advances, such as autologous anti-CD19 chimeric antigen receptor T cells and anti-CD20–CD3 bispecific antibodies.